Evidence map›Paper›PMID 28396835›Full record

ArticleFEBS open bio2017

Using a biologically annotated library to analyze the anticancer mechanism of serine palmitoyl transferase (SPT) inhibitors.

Osamu Sano, Ken-Ichi Kazetani, Ryutaro Adachi, Osamu Kurasawa, Tomohiro Kawamoto, Hidehisa Iwata

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. De Novo Sphingolipid Biosynthesis in Atherosclerosis.Advances in experimental medicine and biology · 2022
    Article
  3. Review
  4. Review
  5. Review
  6. Sphingolipid biosynthesis in man and microbes.Natural product reports · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Osamu SanoBioMolecular Research Laboratories, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Ken-Ichi KazetaniBioMolecular Research Laboratories, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Ryutaro AdachiBioMolecular Research Laboratories, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Osamu KurasawaOncology Drug Discovery Unit, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Tomohiro KawamotoBioMolecular Research Laboratories, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Hidehisa IwataBioMolecular Research Laboratories, Research Takeda Pharmaceutical Company Ltd. Fujisawa Japan.
Takeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanistic understanding is crucial to anticancer drug discovery. Here, we reveal that inhibition of serine palmitoyl transferase (SPT), the rate-limiting enzyme in sphingolipid synthesis, induced death in a lung cancer cell line via a necrosis-dependent pathway. To elucidate the mechanism of cell death induced by SPT inhibition, a biologically annotated library of diverse compounds was screened with an SPT inhibitor. This analysis identified suppressors of SPT inhibitor-mediated cell death. Further analysis using hit compounds from this screening revealed that SPT inhibitors induce COX-2 expression, leading to necrosis-dependent cell death. SPT inhibitors might therefore represent novel candidates for cancer therapy via necrosis pathway regulation. Our data illustrate that compound combination screening of biologically annotated libraries could be used for mechanistic elucidation.

Indexed as

biologically annotated librarycombination screeningCOX‐2necrosisserine palmitoyl transferase

Identifiers

PMID28396835
PMCPMC5377399
OpenAlexW2574110619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.